Treatment of dementia with advanced pharmaceutical technology

An Australian biotechnology company called Philamon Limited has announced the production of a new drug called ALPHA-003 that can stop the progress of dementia. This drug is designed to protect the vital structures of brain cells against damage caused by brain inflammation.

According to Tekna Technology News Media Medical Service, ALPHA-003 helps prevent cell death by maintaining the integrity of microtubules, which are key structural components in nerve cells. This feature can be a turning point in the treatment of diseases such as Alzheimer’s and other types of dementia.

Professor Kieran Scott, professor of oncology at the University of Western Sydney and one of the founders of Philamon, says:
“The main problem in dementia is the destruction of microtubules; Long, hollow structures that are essential for healthy brain function. In affected patients, these structures degenerate and lead to the death of brain cells. So far, no drug has been able to prevent this degradation, but we believe that ALPHA-003 has this ability.”

This drug protects microtubules from damage by stabilizing tau and neurofilament proteins. The destruction of these proteins is one of the main causes of diseases such as Alzheimer’s and chronic encephalopathy.

ALPHA-003 is the result of using advanced drug design technology with the help of deep learning. This drug was first developed as a general anti-inflammatory drug that inhibited the effects of hGIIA enzyme, a key factor in inflammation. But the researchers found that this drug has a special effect on reducing brain inflammation and prevents the formation of toxic clumps in tau protein.

Professor Graham Kelly, CEO of Philamon, says about this drug:
“Our studies showed that ALPHA-003 can prevent the formation of toxic tau clumps and help protect brain cells. This achievement can provide an effective solution for the treatment of dementia.”

Preclinical studies have shown that this drug is able to cross the blood-brain barrier and can directly affect brain cells. Due to the high importance of these results, Philamon’s research team has announced them before their official publication.

Professor Kelly says:
“These results are very new and we decided to announce them early. More studies are underway and their results will be prepared for publication in scientific journals.”

Philamon Company has predicted to receive the necessary permits to conduct clinical trials of this drug by 2026. In addition to Alzheimer’s and frontotemporal dementia, this drug will also be used to treat diseases such as progressive supranuclear palsy and chronic traumatic encephalopathy.

Kelly emphasizes:
“Dementia is a two-stage process; The first stage involves creating chronic inflammation in the brain and the second stage, the consequences of this inflammation. ALPHA-003 attempts to reduce the effects of the second stage. “At the same time, we are also working on another drug that directly targets the trigger of inflammation.”

This revolutionary drug can open a new window for the treatment of neurological diseases and bring hope to millions of patients around the world.